If you've tried countless diets and still can't lose the weight, it's not a failure on your part — and you don't have to do it alone. Our GLP-1 weight loss program pairs FDA-approved semaglutide and tirzepatide with the functional labs that actually explain why weight isn't moving, prescribed by a Florida-licensed nurse practitioner with graduate research in leptin and appetite-regulating hormones.
Branded Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, or compounded semaglutide and tirzepatide from licensed compounding pharmacies — your call, made together at consultation. Every patient gets a full metabolic workup before a single dose is prescribed. In-office at our Miami Beach location, or telehealth statewide across Florida — Orlando, Tampa, Jacksonville, Fort Lauderdale, Boca Raton, Naples, The Villages.
5.0
58 Google Reviews
OWNER · UNIVERSITY OF MIAMI-TRAINED · FL APRN #11005134
FDA-approved branded semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®), or compounded semaglutide/tirzepatide from licensed compounding pharmacies.
Required baseline labs, then customized 3-month starter, then $400/month for refills with weekly check-ins. Exact cost confirmed in writing at consultation.
≈15% body weight loss on semaglutide; ≈21% on tirzepatide (pivotal trial data, paired with nutrition + training).
In-office Miami Beach (1000 5th Street, SoFi). Telehealth statewide across Florida.
Comprehensive metabolic and hormone panel at baseline; repeat at 3–6 months.
Every visit personally led by Kelly Wolfe, MSN, APRN, FNP-BC. No rotating providers.
GLP-1 weight loss medications are injectable drugs — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) — that mimic a hormone your gut already makes after meals. They slow gastric emptying, reduce appetite at the level of the brain, and improve insulin sensitivity. In clinical trials, they produce 15% to 21% average total body weight loss over 12 to 18 months.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by L-cells in the small intestine after you eat. It has three jobs: it tells the pancreas to release insulin in response to glucose, it tells the liver to stop dumping glucose into the bloodstream, and it tells the hypothalamus you’re full. In people with obesity and type 2 diabetes, this signal is weak or short-lived.
GLP-1 receptor agonists are engineered to bind the same receptor but resist the enzyme (DPP-4) that breaks the natural hormone down within minutes. The result is a sustained, amplified version of a satiety signal you already have — held in place for a full week per injection. That’s the entire mechanism behind why people on these medications eat less without willpower, lose meaningful weight, and see A1c, blood pressure, and triglycerides improve alongside it.
Tirzepatide goes one step further. It activates both the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide), a second incretin hormone. The dual mechanism is why tirzepatide produces greater average weight loss than semaglutide in head-to-head studies, and why some patients who plateau on semaglutide respond again when switched.
The FDA-approved indication for GLP-1 anti-obesity medication is a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease. Contraindications include personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, severe gastroparesis, and active pancreatitis.
In our practice, candidacy goes deeper than BMI. The patients who do well on GLP-1 medications share a profile: they have tried structured nutrition, they understand that the medication is one tool inside a larger plan, they are willing to do resistance training to protect lean mass, and they are comfortable with the GI side effects of titration. The patients who struggle are the ones expecting a passive solution.
Florida-specific considerations. Hot, humid climate means dehydration risk on GLP-1 medication is real — reduced thirst plus reduced food intake can drop electrolytes quickly. We talk about this at the first visit and adjust electrolyte and water intake guidance throughout the year.
Tirzepatide produces greater average weight loss than semaglutide — approximately 21% of total body weight at 72 weeks (Zepbound®) versus approximately 15% at 68 weeks (Wegovy®) in pivotal trials. Tirzepatide is a dual GLP-1/GIP agonist; semaglutide is a single-pathway GLP-1 agonist. The right choice depends on tolerance, history, insurance, and budget — not just maximum loss.
| Semaglutide (Wegovy® / Ozempic®) | Tirzepatide (Zepbound® / Mounjaro®) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist (single pathway) | GLP-1 + GIP dual receptor agonist (two pathways) |
| Avg. total body weight loss | ≈14.9% at 68 weeks (STEP-1 trial, NEJM) | ≈20.9% at 72 weeks (SURMOUNT-1 trial, NEJM, highest dose) |
| Dosing | Weekly subcutaneous injection. Titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks | Weekly subcutaneous injection. Titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20 weeks |
| Approved for weight loss | Wegovy® (semaglutide) — yes. Ozempic® (semaglutide) — type 2 diabetes only, used off-label for weight | Zepbound® (tirzepatide) — yes. Mounjaro® (tirzepatide) — type 2 diabetes only, used off-label for weight |
| Side-effect profile | GI (nausea, constipation, reflux). Generally milder than tirzepatide at equivalent stages. | GI (nausea, diarrhea, constipation). Often more pronounced during early titration steps. |
| Cost (cash-pay, branded) | Confirmed at consultation | Confirmed at consultation |
| Real-world track record | Approved 2017 (Ozempic®) / 2021 (Wegovy®). Long-term safety data through 5+ years. | Approved 2022 (Mounjaro®) / 2023 (Zepbound®). Long-term data still accumulating. |
| Best for | Patients new to GLP-1 medication, those who tolerate single-pathway agents well, those prioritizing cost and proven track record | Patients who plateau on semaglutide, those with higher BMI starting weight, those prioritizing maximum loss and metabolic improvement |
Both medications are covered in dedicated depth on our companion pages: Semaglutide weight loss in Florida and Tirzepatide weight loss in Florida. Kelly chooses between them based on your history, your goals, and your tolerance — not a script.
GLP-1 medications work on a graduated dose ladder. You start at a low dose to let the gut adapt, then climb every 4 weeks. Most patients notice reduced appetite and fewer food cravings in the first 1 to 2 weeks. Visible weight loss typically begins around weeks 4 to 8, and meaningful fat loss accelerates once the dose escalates into the therapeutic range around weeks 12 to 16.
Body adapts to GLP-1 mechanism. Mild nausea common. 1–4 lb loss typical, mostly water and appetite-driven.
Appetite suppression becomes obvious. Portion sizes drop naturally. 4–8 lb cumulative loss typical.
Therapeutic-range loss begins. Many patients hit a 5% body-weight milestone here.
Sustained fat loss. Resistance-training and protein protocol becomes non-negotiable to protect lean mass.
Tirzepatide follows the same logic with a longer ladder — 2.5, 5, 7.5, 10, 12.5, and 15 mg over 20 weeks. Some patients reach their goal at 10 mg and never need to climb to 15. The dose that gets you to your goal is the right dose; the maximum-labeled dose is not automatically the target.
Every GLP-1 weight loss patient in our Florida practice gets a comprehensive functional lab panel at baseline. The medication is a tool; the labs explain why your weight is resistant in the first place — and what else needs to be addressed for the medication to actually deliver durable results.
This is the single biggest difference between us and most weight-loss clinics in Florida. A telehealth pill mill writes a Wegovy® script in 12 minutes. We spend an hour on intake and labs because weight resistance is rarely a single problem. Untreated hypothyroidism, undiagnosed insulin resistance, low testosterone, perimenopausal estrogen drop, leptin resistance, cortisol dysregulation, sleep apnea, and vitamin D deficiency all blunt GLP-1 response. Find them, address them, and the medication does more — at a lower dose.
When labs identify a hormone or peptide deficiency driving weight resistance, we often pair GLP-1 therapy with bioidentical hormone optimization or targeted peptide therapy — not as upsells, but because addressing the upstream driver lets the GLP-1 work the way it’s supposed to.
Drawn at any major lab location in Florida. Telehealth patients get an electronic requisition the same day.
Our Florida GLP-1 program begins with required baseline labs and a customized 3-month starter plan tailored to your labs and clinical picture. After the starter program, monthly refills are $400/month and include weekly check-ins, monthly dose adjustments as needed, and ongoing nutrition and program guidance. Branded FDA-approved options (Wegovy®, Ozempic®, Zepbound®, Mounjaro®) are also available; pricing is confirmed in writing at consultation.
Transparent, no surprise add-ons. Our GLP-1 program is structured around required baseline labs, a customized 3-month starter plan, and then ongoing monthly refills. Insurance verification is included in your consultation if you’d like us to run a pharmacy benefits check.
Lab panel required before any GLP-1 prescription. Billed separately.
Tailored to your labs, BMI, dose tolerance, and goals.
Includes weekly check-ins, monthly dose adjustments as needed, and nutrition / program guidance.
South Florida Face and Body prescribes both FDA-approved branded GLP-1 medications (Wegovy®, Ozempic®, Zepbound®, Mounjaro®) and compounded semaglutide and tirzepatide from licensed 503A/503B compounding pharmacies. The right choice depends on your goals, your insurance coverage, your dose, and your budget — and it's a conversation we have at the consultation, not a default we apply to everyone.
Branded GLP-1s are the FDA-approved finished products manufactured by Novo Nordisk (Wegovy®, Ozempic®) and Eli Lilly (Zepbound®, Mounjaro®). They have the longest real-world track record, the cleanest regulatory lineage, and manufacturer-backed pharmacovigilance. List prices without insurance are higher than compounded options, though manufacturer direct-pay programs (Eli Lilly’s LillyDirect®) bring some doses meaningfully lower. We confirm branded pricing in writing at consultation.
Compounded semaglutide and tirzepatide are prepared one prescription at a time at state-licensed 503A or FDA-registered 503B pharmacies. The active ingredient is sourced from FDA-registered API facilities; the finished compounded preparation is not FDA-approved as a finished drug. The benefit is cost (often significantly less than branded) and dose flexibility for intermediate doses not commercially available. The trade-off is regulatory: compounded preparations are not FDA-reviewed for the finished formulation.
We work only with licensed, inspected compounding pharmacies with strong safety records and transparent supply chains. We prescribe compounded GLP-1s as sterile preparations from verified API sources, clearly labeled, with documented sodium-free or salt-form specifications. We will not work with pharmacies we cannot vet, will not write prescriptions for product sourced from non-medical channels, and will not engage with patients sourcing “research peptides” online. Source matters as much as molecule. Patients should avoid anything sold without a prescription, sold internationally, or sold as research-only.
The legal landscape around compounded GLP-1s shifted in 2024–2025 after both tirzepatide and semaglutide came off the FDA shortage list. Compounding under those conditions narrowed and is now constrained to specific patient-need scenarios (dose customization, allergen avoidance, formulation differences). Patients in our Florida program receive a clear written explanation of the regulatory status of branded vs. compounded options at consultation, along with a written quote for each path, before any prescription is written.
Your first visit is 60 to 75 minutes. Kelly personally reviews your full medical history, current medications, weight history, lab history, sleep, training, nutrition, and goals. She then orders the baseline functional panel. You'll have a prescription in hand at the next visit, once labs are reviewed — typically 7 to 14 days later.
Getting started is a four-step process designed to be convenient whether you're across the state or across the causeway.
Kelly is licensed to practice in Florida and sees telehealth patients statewide. Initial visits are conducted via secure video, labs are drawn at a convenient location near you, and FDA-approved branded semaglutide or tirzepatide ships from a licensed pharmacy directly to your home.
The telehealth experience is identical to in-office for everything except the InBody body composition scan — and for many telehealth patients, we use a home-based DEXA scan or local InBody scan as a substitute every 3 to 6 months. Patients across Orlando, Tampa, Jacksonville, Fort Lauderdale, Boca Raton, Naples, Fort Myers, Sarasota, The Villages, Gainesville, Tallahassee, and the Florida Keys receive the same level of provider attention as patients walking into our Miami Beach office.
If you're on an adequate dose of semaglutide or tirzepatide and not losing weight — or you've hit a plateau, or the stubborn belly fat isn't budging — three things are usually true: the dose is below the therapeutic range, an underlying metabolic driver (thyroid, insulin resistance, hormones) is unaddressed, or lean mass is being lost instead of fat, which slows metabolic rate and stalls the scale. We've reversed this pattern in dozens of patients who came to us frustrated with a prior clinic.
The most common scenarios we see at consultation:
Without a maintenance plan, weight regain after stopping GLP-1 medication is the published norm — patients in the STEP-1 extension regained approximately two-thirds of lost weight within one year of discontinuation. With a structured taper, the picture is different. In Kelly's practice, every patient who has completed the program has held their goal weight and preserved lean mass on follow-up — measured by InBody scan and at-home smart-scale data.
The way Kelly runs the off-ramp matters. At goal weight, she designs a customized tapering protocol — specific adjustments to dose and injection timing, paired with a caloric balance and nutrition program calibrated to the patient’s new weight and lifestyle. Some patients choose to stay on a low maintenance “micro-dose” long-term to keep metabolic biomarkers (A1c, fasting insulin, lipids, inflammation) optimized. Others taper the dose down slowly to full discontinuation. The right approach depends on the patient — their goals, their lab markers, and how their body responded during the loss phase.
The four pillars that make this work are built during the weight-loss phase, not bolted on at the end:
Kelly is the owner of South Florida Face and Body. A board-certified Family Nurse Practitioner trained at the University of Miami, she holds advanced degrees in nursing, biochemistry, and biology — with graduate research focused on metabolism and the role of leptin and appetite-suppressing hormones. She is also a Certified Functional Medicine Practitioner.
That research background is uncommonly relevant for GLP-1 work. Leptin is the hormone that tells the brain it has enough fuel; appetite-suppressing hormones — including the GLP-1 system itself — are the downstream signaling Kelly studied. The questions she asks at consultation are not pamphlet-level; the lab markers she orders reflect what she actually understands about why weight is resistant.
And she owns the practice. The person you book with is the person who reviews your history, interprets your labs, writes your prescription, and walks you through the protocol — every visit, no exceptions, no rotating providers, no handoffs.
Same-week consultations available. South of Fifth, Miami Beach.
Kelly is licensed to provide medical weight loss care via telehealth to patients throughout Florida. Video consults, lab orders sent to a convenient location near you, and FDA-approved branded medication shipped directly to your home from a licensed pharmacy.
Kelly is the owner of South Florida Face and Body. A board-certified Family Nurse Practitioner trained at the University of Miami, she holds advanced degrees in nursing, biochemistry, and biology, with graduate research focused on metabolism and the role of leptin and appetite-suppressing hormones. She practices at the intersection of functional medicine and aesthetic injection — meaning the conversations in her treatment room often go beyond the syringe to consider sleep, hormones, metabolism, and inflammation as part of how your skin and face actually present.
Licensed as an Advanced Practice Registered Nurse in the State of Florida (APRN #11005134), Kelly brings more than three decades of experience in health, fitness, and clinical practice. She has performed aesthetic injections in South Florida for over a decade and has trained alongside the dermatology and plastic surgery community that built Miami’s aesthetic reputation.
She is the one who answers your text message. She is the one who calls the day after your injection.
From your first consultation through every follow-up, you’ll work directly with Kelly — one injector, one set of hands, one consistent plan.
Advanced practice registered nursing with a focus on family health and primary care.
Research focused on metabolism and the role of leptin and appetite-suppressing hormones.
Research with a strong foundation in human physiology, cellular biology, and biochemistry.
National certification in family practice and primary care.
Authorized to diagnose, treat, and prescribe medications in the State of Florida.
Advanced training in root-cause diagnostics, hormone optimization, metabolic health, and integrative wellness.
Over 30 years helping clients achieve sustainable health and wellness transformations.
The questions Florida patients ask most often before starting GLP-1 weight loss. If yours isn't covered here, Kelly is happy to answer directly — text or call.
Our Florida GLP-1 weight loss program begins with required baseline labs (billed separately) and a customized 3-month starter plan tailored to your labs, starting BMI, and clinical picture. After the starter program, compounded semaglutide or tirzepatide refills are $400/month and include weekly check-ins, monthly dose adjustments as needed, and ongoing nutrition and program guidance.
Branded FDA-approved GLP-1 medications are also available for patients who prefer them — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®). Pricing for branded options is confirmed in writing at consultation based on dose and source. Eli Lilly’s LillyDirect® self-pay program brings some branded tirzepatide doses meaningfully lower.
Labs are required before any GLP-1 prescription can be written. Exact starter-program cost is confirmed in writing at consultation.
GLP-1 weight loss therapy is FDA-approved for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related comorbidity — type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease.
Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastroparesis, or active pancreatitis are not candidates. Pregnancy, planning pregnancy, breastfeeding, and active eating disorder are also exclusions. Kelly personally reviews every health history before prescribing.
Tirzepatide produces greater average weight loss in head-to-head data — approximately 21% of total body weight at 72 weeks (Zepbound®) versus approximately 15% at 68 weeks (Wegovy®). Tirzepatide is a dual GLP-1 and GIP receptor agonist, which broadens its mechanism.
Semaglutide has a longer real-world track record, often costs less, and is the right choice for many patients — particularly those who tolerate single-pathway GLP-1 well, or who want to start with the agent that has 5+ years of post-approval safety data.
The decision is made one patient at a time based on goals, tolerance, history, and budget. See our dedicated pages on semaglutide and tirzepatide for the deeper dive.
Yes. Kelly is licensed to practice in Florida and provides GLP-1 weight loss care via telehealth to patients throughout the state, including Orlando, Tampa, Jacksonville, Fort Lauderdale, Boca Raton, Naples, Fort Myers, Sarasota, The Villages, Gainesville, Tallahassee, and West Palm Beach.
The initial visit is conducted via secure video. Baseline labs are drawn at a convenient lab location near you. FDA-approved branded semaglutide or tirzepatide is sent directly from a licensed pharmacy to your home. Monthly check-ins continue via telehealth.
Patients in Miami Beach and surrounding South Florida can choose in-office or hybrid telehealth visits.
Yes. South Florida Face and Body prescribes both FDA-approved branded medications — semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) — and compounded semaglutide or tirzepatide from licensed 503A/503B compounding pharmacies, depending on the patient’s clinical picture, goals, and budget.
The legal landscape around compounded GLP-1s shifted in 2024–2025 once both molecules came off the FDA shortage list. Compounding under those conditions is now constrained to specific patient-need scenarios (dose customization, allergen avoidance, formulation differences) and we work only with licensed, inspected compounding pharmacies with verifiable supply chains.
Patient safety is the variable that doesn’t move. We will not work with pharmacies we cannot vet, will not write prescriptions for product sourced from non-medical channels, and will not engage with patients sourcing “research peptides” online. Patients should avoid anything sold without a prescription, sold internationally, or sold as research-only — those carry real documented risks of dosing errors, contamination, and unverified salt forms (semaglutide acetate, semaglutide sodium).
Most patients notice reduced appetite and fewer cravings within the first 1 to 2 weeks. Visible weight loss typically begins around weeks 4 to 8, once the dose climbs into the therapeutic range.
The sustainable pace is roughly 1 to 2 pounds per week of fat loss — slower, deliberate loss that holds, rather than rapid loss that leads to regain. The full benefit is observed at 12 to 18 months on a maintenance dose, with average total body weight loss of approximately 15% on semaglutide and 21% on tirzepatide when paired with structured nutrition and resistance training.
Patients who do not reach a therapeutic dose, or who do not protect lean mass with protein and strength training, see meaningfully smaller results.
Baseline functional lab work for GLP-1 weight loss in our practice includes:
CBC, comprehensive metabolic panel, hemoglobin A1c, fasting insulin, fasting glucose, full lipid panel + ApoB, full thyroid panel (TSH, free T3, free T4, reverse T3), leptin, vitamin D, ferritin, B12, sex hormones (testosterone, estradiol, progesterone, DHEA-S, SHBG), AM cortisol, and inflammatory markers (hs-CRP, homocysteine).
These labs identify the metabolic drivers behind weight resistance — thyroid dysfunction, insulin resistance, leptin resistance, sex hormone deficiency, cortisol dysregulation, inflammation — and ensure GLP-1 medication is the right tool, not a workaround for an unaddressed problem. Labs are repeated at 3 to 6 months to track progress.
The most common side effects of semaglutide and tirzepatide are gastrointestinal: nausea, decreased appetite, constipation, diarrhea, and occasional reflux. These are typically dose-dependent, peak in the first one to two weeks after each dose escalation, and resolve as the body adapts.
Less common but more serious side effects include pancreatitis, gallbladder disease, severe gastroparesis, and acute kidney injury from dehydration. Both medications carry a boxed warning for thyroid C-cell tumors observed in rodent studies; patients with a personal or family history of medullary thyroid carcinoma or MEN-2 should not take these medications.
Patients on anticoagulant or antiplatelet medication (aspirin, warfarin, Plavix, Eliquis, Xarelto) should disclose all current medications during your consultation. Do not discontinue any anticoagulant on your own — always consult your prescribing physician before making any changes to these medications.
The published trial data is real: STEP-1 extension patients regained approximately two-thirds of lost weight within one year of discontinuation when no maintenance protocol was in place.
With a structured off-ramp, that’s not what we see. In Kelly’s practice, patients who reach their goal weight and follow the customized tapering plan have held their weight and preserved lean mass on follow-up — measured by InBody scan and at-home smart-scale data.
At goal weight, Kelly designs a personalized taper: specific dose and timing adjustments paired with a sustainable nutrition program. Some patients stay on a low “micro-dose” long-term to keep metabolic biomarkers optimized. Others slowly reduce the dose to full discontinuation. The right approach depends on the patient — not a default.
Coverage is inconsistent and changes frequently. Some Florida Blue, Aetna, Cigna, and UnitedHealthcare plans cover Wegovy® or Zepbound® for weight loss when prior authorization criteria are met — typically requiring documented BMI thresholds and a weight-loss-related comorbidity.
Most plans do not cover Ozempic® or Mounjaro® for off-label weight loss when there is no type 2 diabetes diagnosis. Florida Medicaid coverage for GLP-1 anti-obesity medications remains limited. Compounded GLP-1s are cash-pay.
Patients should call the member services number on their insurance card before their first visit. We can also run a pharmacy benefits check during your consultation.
Yes. We see this often — patients who started Wegovy® or Zepbound® at a telehealth mill, plateaued, and want a real provider to figure out why.
The most common reasons we find at consultation are sub-therapeutic dose, untreated thyroid or insulin issues, leptin resistance, loss of muscle mass, perimenopausal hormone shifts, or cortisol dysregulation. The fix is rarely “switch to a different GLP-1” — it’s identifying the upstream driver and addressing it alongside the medication.
Our in-person office is at 1000 5th Street, Suite 414, Miami Beach, FL 33139, in the South of Fifth (SoFi) neighborhood. Parking is available in the attached garage at $4 per hour, and free street parking is available around the building during business hours (one nearby zone is pay-to-park — signage will indicate).
South Florida patients in Miami Beach, Miami, Brickell, Fort Lauderdale, and Boca Raton are typically seen in-office for the initial visit. Patients elsewhere in Florida are seen via telehealth. Phone: (786) 529-1860.
In most cases yes, but it requires disclosure and planning. GLP-1 medications themselves do not interact with anticoagulants, but injection-site bruising can be more pronounced. Please disclose all current medications during your consultation — including aspirin, warfarin, Plavix, Eliquis, Xarelto, or any other anticoagulant or antiplatelet medication.
Important: do not discontinue any anticoagulant on your own. Always consult your prescribing physician before making any changes to these medications.
Trademark notice. Wegovy®, Ozempic®, and Rybelsus® are registered trademarks of Novo Nordisk A/S. Zepbound®, Mounjaro®, and LillyDirect® are registered trademarks of Eli Lilly and Company. InBody® is a registered trademark of InBody Co., Ltd. Eliquis® is a registered trademark of Bristol-Myers Squibb Pharma Company. Xarelto® is a registered trademark of Bayer Aktiengesellschaft. Plavix® is a registered trademark of Sanofi-Aventis. Pradaxa® is a registered trademark of Boehringer Ingelheim. All other trademarks referenced are the property of their respective owners.
No affiliation. South Florida Face and Body is not affiliated with, endorsed by, sponsored by, or otherwise associated with Novo Nordisk A/S, Eli Lilly and Company, InBody Co., Ltd., or any other manufacturer of the medications or products referenced on this page. Use of these trademarks is solely for accurate identification of FDA-approved medications and for the educational benefit of our patients. References to brand-name medications do not imply that we dispense, distribute, or recommend any specific manufacturer’s product over compounded alternatives. Treatment decisions, including the choice between branded and compounded semaglutide or tirzepatide, are made between the patient and Kelly Wolfe, MSN, APRN, FNP-BC, based on individual clinical factors.
Medical disclaimer. The content on this page is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Clinical statistics cited (including STEP-1, SURMOUNT-1, SURMOUNT-4, and SURMOUNT-5 trial data) reflect published clinical trial averages and do not guarantee individual results. GLP-1 receptor agonists are prescription medications that require medical evaluation, ongoing supervision, and are not appropriate for every patient. Always consult a qualified healthcare provider before starting, stopping, or changing any medication — including semaglutide, tirzepatide, and any anticoagulant or other prescription drug you may currently take. If you experience a medical emergency, call 911.
Compounded medications notice. Compounded semaglutide and tirzepatide are prepared by state-licensed 503A or FDA-registered 503B pharmacies and are not the same product as FDA-approved Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. Compounded medications are not reviewed by the FDA for safety, efficacy, or quality prior to dispensing. The FDA has not approved compounded semaglutide or compounded tirzepatide. Patients in our Florida program receive a clear explanation of the differences between branded and compounded formulations at consultation and choose accordingly.
